International AIDS Vaccine Initiative (IAVI)

iavi.org

The International AIDS Vaccine Initiative (IAVI) is a nonprofit scientific organization whose mission is to develop vaccines and other biomedical innovations that prevent HIV infection. Since its founding in 1996, IAVI has provided scientific, research and development, and policy leadership to address the needs of communities and key populations at risk for HIV infection around the world. IAVI works with more than 100 academic, industry, government, civil society, clinical, and community partners in more than 25 countries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

DEEPINTENT ADDS MORE LEADING DATA PROVIDERS TO ITS AUDIENCE MARKETPLACE, SIMPLIFYING PHARMA CAMPAIGN PLANNING AND OPTIMIZATION

DeepIntent | July 14, 2022

news image

DeepIntent, the leading healthcare advertising technology company built to influence better patient health and business outcomes announced the addition of audience segments from Redi-Data, MedFuse, HealthWise Data, Prognos Health, and TV viewership data from LG Ads Solutions to the DeepIntent Audience Marketplace. These segments are directly integrated into DeepIntent's demand side platform for immediate activation, with the ability to optimize campaigns in real-time toward au...

Read More

Business Insights

HIKMA STRENGTHENS US INJECTABLES BUSINESS THROUGH ACQUISITION OF CUSTOPHARM

Hikma Pharmaceuticals USA Inc. | September 27, 2021

news image

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'). Hikma will pay an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certa...

Read More

Business Insights, PHARMA TECH

NEOCHROMOSOME ANNOUNCES SUCCESSFUL COLLABORATION WITH SUMITOVANT BIOPHARMA

Sumitovant Biopharma, Inc. | January 20, 2023

news image

On January 19, 2023, Neochromosome, Inc., announced a partnership with Sumitovant Biopharma, Inc., a technology-driven biopharmaceutical firm expediting the discovery and commercialization of novel therapeutics. This collaboration blends Neochromosome's neoYeast™ platform with Sumitovant's DrugOME™ computational ecosystem to identify new proteins that would benefit from non-canonical amino acid chemistries that are unavailable in nature. As part of...

Read More

HOW EHR-INTEGRATED PDMPS INCREASE INTEROPERABILITY, DECREASE BURDEN

EHRIntelligence | March 11, 2020

news image

A prescription drug monitoring program (PDMP) that is implemented into the EHR can decrease the strenuous process of checking the PDMP, thus reducing the cognitive workload and burden for the clinician. However, only one-in-three hospitals can access PDMP data within its EHR system. PDMPs are state-run electronic databases that have been deployed in 49 states, excluding Missouri. The program collects data from pharmacies on Drug Enforcement Agency (DEA) controlled substances and prescription dru...

Read More
news image

Business Insights

DEEPINTENT ADDS MORE LEADING DATA PROVIDERS TO ITS AUDIENCE MARKETPLACE, SIMPLIFYING PHARMA CAMPAIGN PLANNING AND OPTIMIZATION

DeepIntent | July 14, 2022

DeepIntent, the leading healthcare advertising technology company built to influence better patient health and business outcomes announced the addition of audience segments from Redi-Data, MedFuse, HealthWise Data, Prognos Health, and TV viewership data from LG Ads Solutions to the DeepIntent Audience Marketplace. These segments are directly integrated into DeepIntent's demand side platform for immediate activation, with the ability to optimize campaigns in real-time toward au...

Read More
news image

Business Insights

HIKMA STRENGTHENS US INJECTABLES BUSINESS THROUGH ACQUISITION OF CUSTOPHARM

Hikma Pharmaceuticals USA Inc. | September 27, 2021

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'). Hikma will pay an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certa...

Read More
news image

Business Insights, PHARMA TECH

NEOCHROMOSOME ANNOUNCES SUCCESSFUL COLLABORATION WITH SUMITOVANT BIOPHARMA

Sumitovant Biopharma, Inc. | January 20, 2023

On January 19, 2023, Neochromosome, Inc., announced a partnership with Sumitovant Biopharma, Inc., a technology-driven biopharmaceutical firm expediting the discovery and commercialization of novel therapeutics. This collaboration blends Neochromosome's neoYeast™ platform with Sumitovant's DrugOME™ computational ecosystem to identify new proteins that would benefit from non-canonical amino acid chemistries that are unavailable in nature. As part of...

Read More
news image

HOW EHR-INTEGRATED PDMPS INCREASE INTEROPERABILITY, DECREASE BURDEN

EHRIntelligence | March 11, 2020

A prescription drug monitoring program (PDMP) that is implemented into the EHR can decrease the strenuous process of checking the PDMP, thus reducing the cognitive workload and burden for the clinician. However, only one-in-three hospitals can access PDMP data within its EHR system. PDMPs are state-run electronic databases that have been deployed in 49 states, excluding Missouri. The program collects data from pharmacies on Drug Enforcement Agency (DEA) controlled substances and prescription dru...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us